Benzyl Alcohol–Benzyl Benzoate Co-Solvent Ratios and Terminal Sterilization Limits in NPP Oil-Based Injectables

Nandrolone phenylpropionate veterinary grade API exhibits a melting point of approximately 95–98°C and aqueous solubility below 0.05 mg/mL at 25°C, necessitating non-aqueous vehicle systems for injectable presentations intended for intramuscular or subcutaneous administration in equine and companion animal species. The API is dissolved in a co-solvent matrix composed of benzyl alcohol (BP/Ph.Eur. certified) at 5–10% v/v and benzyl benzoate at 10–20% v/v, then diluted to final volume with refined sesame oil conforming to Ph.Eur. monograph 0432 or USP sesame oil monograph, or alternatively with ethyl oleate or medium-chain triglycerides where lower injection-site viscosity is specified. Dissolution is carried out in jacketed stainless steel vessels fabricated from 316L alloy with internal surfaces mirror-polished to Ra ≤ 0.4 μm, maintained under a nitrogen overlay to limit oxidative degradation, with heating at 40–45°C and propeller agitation at 60–120 rpm until visual clarity is confirmed by inspection against a light source. The completed bulk solution is passed through a 0.22 μm PVDF or PTFE cartridge membrane filter qualified for oil-based products, then filled into USP Type I borosilicate glass vials or glass ampoules within a Grade A laminar air flow cabinet conforming to EU GMP Annex 1. Terminal sterilization by saturated steam autoclaving at 121°C for 15 minutes is standard; however, cumulative thermal exposure above 30 minutes at sterilization temperature or repeated autoclaving cycles promotes measurable ester hydrolysis to free nandrolone, detected by HPLC assay loss and free sterol related substance increase. Benzyl alcohol is susceptible to oxidative conversion to benzaldehyde, producing a characteristic almond odor and detectable aldehyde impurity by headspace GC, which defines the practical boundary for holding bulk solution at elevated temperature. Post-sterilization release testing must include sterility per USP <71>, bacterial endotoxins per USP <85> with a limit of ≤ 0.5 EU/mg, particulate matter per USP <788> (≥ 10 μm: ≤ 6000 particles/container; ≥ 25 μm: ≤ 600 particles/container), visible particulates per USP <790>, and content uniformity per USP <905> where unit dose < 2 mL. Syringability testing through a 23G needle at 25°C should produce an extrusion force not exceeding 15 N for a 2 mL fill volume. Typical veterinary injectable strengths are 25 mg/mL and 50 mg/mL, with benzyl alcohol acting as both co-solvent and local anesthetic adjunct. Batch retention samples stored at 25°C/60% RH in photoprotective secondary cartons should maintain assay between 95–105% of label claim for 24 months under ICH Q1A(R2) stability protocols.

Manufacturing scale-up of oil-based NPP injections introduces specific process bottlenecks not observed at laboratory scale. High-shear rotor-stator mixing intended to accelerate API dissolution entrains nitrogen microbubbles into the viscous oil phase, which subsequently interfere with downstream filtration throughput and constitute visible particulate defects after terminal sterilization. Vacuum deaeration at −0.8 bar for 30–60 minutes with slow paddle agitation is required prior to sterile filtration. Filling line hold times exceeding 8 hours at 20–25°C under ambient lighting conditions can produce measurable peroxide accumulation in sesame oil, quantified by Ph.Eur. monograph 2.5.5 peroxide value testing; specification limits are typically ≤ 5.0 meq O₂/kg. Single-use versus stainless steel filling system compatibility must be validated with the co-solvent system, because benzyl alcohol demonstrates extractive potential with certain silicone tubing grades and elastomeric seals. Annex 1 compliance for Grade C background with Grade A filling requires environmental monitoring for total particle counts (≥ 0.5 μm at rest: ≤ 352,000/m³; in operation: ≤ 3,520,000/m³) and viable counts (≤ 10 CFU/m³ in Grade A). Filling accuracy tolerances for 2 mL fill volumes are typically ± 0.1 mL with a validated peristaltic or piston pump system, and in-process checks are performed every 15 minutes per batch record. The API ester chain confers moderate depot activity; in sesame oil vehicles, phenylpropionate ester release kinetics yield a terminal half-life in canines reported in veterinary pharmacology literature as approximately 2–4 days following a single intramuscular dose, compared with 10–14 days for the nandrolone decanoate ester. This shorter duration is advantageous when veterinary clinicians require recoverable suppression of endogenous gonadal steroid output or when repeated dosing must be withdrawn rapidly for elective procedures.

Terminal product documentation for export markets requires the certificate of analysis to reference specific monographs; several pharmacopoeial monographs for nandrolone esters include related substance limits expressed as individual specified impurities ≤ 0.5% and total unspecified impurities ≤ 1.0% by area normalization HPLC. Residual solvent testing per USP <467> or Ph.Eur. 2.4.24 is mandatory when benzyl alcohol and benzyl benzoate are used as co-solvents, with benzyl alcohol classified as ICH Q3C Class 3 (permitted daily exposure ≤ 50 mg/day) and benzyl benzoate similarly Class 3. Container closure integrity testing using vacuum decay or helium leak detection per USP <1207> validates the glass vial and rubber stopper seal over the assigned shelf life. Sterile injectable NPP products for veterinary use in the United States require an approved New Animal Drug Application (NADA) or are compounded under the Animal Medicinal Drug Use Clarification Act (AMDUCA) provisions within 21 CFR 530; EU marketing requires centralised or national veterinary marketing authorisation per Directive 2001/82/EC as amended. Products intended for equine competition use carry additional restrictions, because nandrolone phenylpropionate is classified as a prohibited substance by the Fédération Équestre Internationale (FEI) Equine Prohibited Substances List; urine detection windows in equines following 25 mg intramuscular doses have been reported to extend to 30–90 days depending on ester chain and formulation matrix, which must be disclosed on product labeling where applicable.

Within companion animal veterinary practice, nandrolone phenylpropionate is formulated into immediate-release oral tablets for dogs and cats, with doses commonly in the range of 5–25 mg per unit. Direct compression is the preferred manufacturing route when the API particle size distribution falls within 50–150 μm D₅₀; however, NPP exhibits cohesive powder characteristics at low moisture content, causing die filling variability on high-speed rotary tablet presses at turret speeds above 40 rpm. Wet granulation with polyvinylpyrrolidone K30 at 2–5% w/w as aqueous binder solution improves flowability and compressibility but introduces a drying step during which the ester linkage must be protected from excessive heat exposure. The granulation mass is dried in a fluidized bed dryer with inlet air temperature set at 50–55°C and endpoint loss on drying of 2–4% by moisture balance per USP <731>; exceeding 65°C during drying produces measurable degradation of the phenylpropionate ester, with HPLC analysis showing nandrolone free alcohol as the primary degradation marker. Lubrication with magnesium stearate at 0.5–1.0% w/w is performed for 3–5 minutes in a V-blender; extended lubrication beyond 10 minutes produces a hydrophobic film on granule surfaces that delays tablet disintegration. Disintegrant selection favors croscarmellose sodium at 2–5% w/w intragranularly with an equal portion extragranularly, providing disintegration times below 15 minutes in purified water at 37±2°C per USP <701>. Tablet hardness specifications for veterinary oral tablets are typically 5–8 kP (49–78 N) using a calibrated hardness tester, with friability below 1.0% after 100 revolutions per USP <1216>. The low aqueous solubility of NPP means that content uniformity across tablets weighing 100–200 mg total must be verified by USP <905> acceptance value criteria (AV ≤ 15.0) rather than by weight variation alone, because segregation of the API during blending is a documented failure mode when the API particle size is finer than 30 μm. Dissolution testing using USP Apparatus II at 50 rpm with 900 mL of 0.5% w/v sodium lauryl sulfate in 0.1 M hydrochloric acid at 37±0.5°C provides discriminatory release data; specifications typically require not less than 70% dissolved at 45 minutes per USP <711>. Published dissolution data for NPP veterinary tablets in biorelevant media is limited across different species-specific gastric pH conditions, so development validation should include dissolution profiles at pH 1.2, 4.5, and 6.8 to satisfy ICH Q6A decision trees where applicable.

The oral tablet manufacturing process for NPP must address two specific compliance boundaries. First, tablet tooling that produces excessive shear during compression can raise tablet core temperatures by 3–8°C depending on compression force and turret speed, which is significant because the API ester is susceptible to thermomechanical degradation when formulation pressure exceeds 150 MPa. Precompression force should be limited to 2–4 kN with main compression force between 8–12 kN for a 10 mm round concave tooling. Second, compatibility between NPP and common veterinary chewable tablet excipients including liver powder, brewer's yeast, and meat-derived flavorings has not been systematically published in peer-reviewed literature, and formulators should perform binary compatibility studies at 40°C/75% RH for 4 weeks with HPLC monitoring for ester hydrolysis before committing to a production formulation. Batch sizes on a 16-station rotary tablet press running at 30–35 rpm typically yield 120,000–200,000 tablets per shift; tablet weight, hardness, and thickness are sampled every 15–30 minutes with in-process control charts. Post-compression coating with hydroxypropyl methylcellulose (HPMC) at 2–3% w/w weight gain in a perforated pan coater provides taste masking and moisture protection, but coating pan inlet temperatures above 60°C are to be avoided, and the aqueous coating suspension should not exceed 10% w/w solids content to prevent over-wetting of the compressed tablet core. Stability storage of uncoated NPP tablets in high-density polyethylene (HDPE) bottles with desiccant canisters under 25°C/60% RH per ICH Q1A(R2) zone II conditions maintains assay within 95–105% for up to 36 months based on bracketed stability protocols; however, blister packaging with PVC/PVDC foil offers superior moisture barrier where geographic distribution includes zone IVb (hot and very humid) conditions.

What Determines Blend Homogeneity Limits in Low-Dose Nandrolone Phenylpropionate Capsule Manufacture?

The capsule presentation of NPP for veterinary use is driven by the need for flexible dose titration in feline and small-breed canine patients, where unit doses of 2.5 mg, 5 mg, and 10 mg are compounded or manufactured. Capsule filling of low-dose NPP blends presents a statistically defined homogeneity challenge: when the API represents less than 5% w/w of the total powder blend, the probability of acceptable content uniformity per USP <905> acceptance value criteria decreases sharply unless geometric dilution is employed in multiple discrete steps. The API is first triturated with an equal mass of lactose monohydrate (Ph.Eur./USP certified, D₅₀ 75–100 μm) using a mortar and pestle or a low-shear tumble blender, then successively diluted with additional bulk filler until the final blend concentration is reached. For a 2.5 mg capsule using a Size 3 capsule with a target fill weight of 120 mg, the final blend strength is 2.08% w/w; this requires not fewer than 5 geometric dilution steps to achieve a relative standard deviation below 5% across ten sampling locations, as verified by HPLC assay. The final blend is passed through a 30-mesh (600 μm) sieve to break up any agglomerates and then lubricated with magnesium stearate at 0.25–0.5% w/w for not more than 3 minutes to minimize hydrophobic surface coating of API particles. Filling is performed on a semi-automatic capsule filling machine with weight monitoring by in-process checkweighing; target weight variation for a 120 mg fill is ± 5 mg (equivalent to ± 4.2%), which propagates to an API content variation of ± 4.2% before analytical variability is considered. Starch-derived capsule shells (HPMC or gelatin) are preferred over pullulan where moisture content of the filled capsules is below 4%, because HPMC shells at low equilibrium relative humidity become brittle and may exhibit shell cracking or splitting during automated filling, particularly when the fill weight exerts radial pressure on the shell body. Lubricant selection for low-fill-weight capsules should avoid talc at concentrations above 2% w/w, because talc exhibits a high surface area and adsorbs NPP from the blend, reducing dissolution recovery and producing a systematic assay bias at the lower specification limit.

Dissolution testing of NPP capsules must accommodate two distinct release environments: the fasted canine stomach (pH approximately 1.5–2.5) and the fasted feline stomach (pH approximately 2.0–3.5). The phenylpropionate ester demonstrates negligible aqueous solubility at pH 4.5 and 6.8 buffer media, so the inclusion of surfactant is mandatory to achieve sink conditions. A validated dissolution method using USP Apparatus II at 50 rpm with 900 mL of 0.5% w/v sodium lauryl sulfate in 0.05 M phosphate buffer adjusted to pH 6.8 provides sink conditions exceeding 3× the highest dosage strength dissolved. Published peer-reviewed dissolution data for nandrolone phenylpropionate capsules in veterinary species-specific media is limited; the USP <1092> guidance on method development therefore recommends establishing an in vitro–in vivo correlation where feasible, but for veterinary compounded products the practical specification is often ≥ 75% released at 60 minutes as a minimum threshold with full profile comparison across three pH conditions. Stability studies for capsules in HDPE bottles at 25°C/60% RH and 40°C/75% RH (accelerated) per ICH Q1A(R2) should include testing for content uniformity at the smallest capsule strength, because low-dose capsules are most sensitive to API migration into gelatin shells and moisture-induced hydrolysis of the ester. The free nandrolone related substance specification for capsules should generally match the API specification, with individual impurity limits ≤ 0.5% and total unspecified ≤ 1.0% by HPLC area normalization, unless justified by formulation-specific degradation studies.

Feed-grade blending of nandrolone phenylpropionate into premix and meal formulations is practiced in jurisdictions where anabolic steroid growth promotion in food-producing species remains legally permitted, although the European Union has prohibited all such uses since Directive 96/22/EC with subsequent amendments, and the Codex Alimentarius Commission recommends zero residue tolerance for nandrolone in food animal tissues. Where legal, premix manufacture requires geometric dilution of the API into a carrier such as ground corn cob fractions, calcium carbonate, or soybean hulls at specifications that support subsequent mixing into complete feed. The API concentration in a standard veterinary premix is typically 1–5 g/kg (equivalent to 0.1–0.5% w/w), with the carrier particle size range of 250–850 μm (approximately 20–60 mesh US Standard) chosen to prevent segregation during bulk transport and to match the particle size distribution of the finished feed matrix. Homogeneity of the premix is verified by sampling at 10 locations using a slotted grain probe per ISO 6497:2002 (Animal feeding stuffs – Sampling), with the coefficient of variation of API concentration not exceeding 5% across all sample points. Mixing equipment for premix production typically includes horizontal ribbon mixers with a working capacity of 500–2000 kg; mixing time is validated by tracer studies using iron powder or salt tracers per ISO 6498:2012, with the optimal mixing time for a 1000 kg ribbon mixer typically falling between 8–15 minutes at rotor speeds producing a tip speed of 1.5–2.5 m/s. Extended mixing beyond the validated optimum can produce static charge accumulation in low-humidity environments (relative humidity below 40%), causing API particles to adhere to mixer walls and reducing assay recovery at subsequent sampling points. The finished premix is packaged in multi-wall paper bags with polyethylene inner liner, labeled with the withdrawal period where applicable; withdrawal period determination for nandrolone phenylpropionate in meat-producing species follows the target tissue residue depletion kinetics, with published data indicating that steroid esters accumulate in adipose tissue and can exhibit prolonged detection windows exceeding 60 days post-administration depending on dose and individual animal metabolic rate. Export documentation must reference GMP+ FSA feed safety assurance or FAMI-QS certification for feed additives, and the certificate of analysis must include heavy metal limits (lead ≤ 5 ppm, arsenic ≤ 3 ppm, cadmium ≤ 1 ppm, mercury ≤ 0.1 ppm by ICP-MS per EN 17053) and dioxin/PCB screening where the destination market requires it under Regulation EC 183/2005.

Feed premix applications of NPP introduce a specific analytical challenge: extraction efficiency of the steroidal ester from high-fat feed matrices is matrix-dependent and may underestimate assay if a simple solvent shake-out is employed. Validated extraction protocols using accelerated solvent extraction (ASE) or microwave-assisted extraction with a ternary solvent system such as methanol:acetonitrile:ethyl acetate (2:2:1 v/v/v) are required to achieve recoveries between 85–110% at spiked concentrations of 0.5–5 mg/kg. Detection and quantification are performed by LC-MS/MS in multiple reaction monitoring mode using a deuterated internal standard such as nandrolone-d₃, with method detection limits below 0.1 μg/kg for confirmation of compliance with maximum residue limits (MRLs) where applicable; the European Union enforces a recommended concentration for non-compliant detection at 1 μg/kg for nandrolone in bovine urine under Commission Decision 2002/657/EC performance criteria. The use of nandrolone phenylpropionate in food-producing animals is banned in the EU, China, and several Latin American export markets; procurement documentation should therefore specify the destination market and legal status before dispatch, because re-export or transshipment through prohibited jurisdictions can trigger customs seizure under the Rotterdam Convention guidelines for veterinary drug residues. Within the United States, anabolic steroid use in food animals is not permitted under 21 CFR 522 unless a specific FDA approval exists, and extra-label use of approved steroid products in food animals is prohibited by 21 CFR 530.41; this regulatory boundary defines the practical market scope for NPP feed premixes primarily to jurisdictions with differing national legislation. Particle attrition of the carrier material during pneumatic conveying can generate fines below 100 μm that segregate during discharge, and premix formulations are therefore tested for particle size distribution by sieve analysis per ISO 2591-1:2008 to control the fines fraction below 5% w/w through that mesh fraction. A representative premix batch record should also include a mixing curve validation report demonstrating that the selected mixing time achieves plateaus in tracer concentration measurements rather than transient mixing peaks, because ordered mixing mechanisms with cohesive fines can produce temporary homogeneity that is lost upon discharge and subsequent handling.

When Fluidized Bed Drying Replaces Tray Drying for NPP Granules Destined for Oral Administration

The granulated form of nandrolone phenylpropionate for veterinary oral dosing is prepared by wet granulation using an aqueous binder solution, where the choice of dryer configuration directly determines granule porosity, residual moisture, and API degradation profile. A top-spray fluidized bed dryer with inlet air temperature controlled at 50–55°C and air flow rate adjusted to maintain product bed temperature at 35–40°C is preferred over forced-air tray drying, because tray drying produces a moisture gradient across the granule bed with the lower layer retaining 1–2% higher moisture content than the upper layer, which in turn produces non-uniform ester hydrolysis rates during storage. The granulation liquid consists of polyvinylpyrrolidone K30 at 5% w/v in purified water, sprayed at a rate of 1.5–2.5 g/minute per kg of dry powder charge; the total binder addition targets 2–4% w/w dry basis. The dry powder charge before granulation includes NPP API, lactose monohydrate as diluent, and microcrystalline cellulose PH101 at 10–20% w/w as a compressibility enhancer for subsequent tableting or for direct filling into unit-dose sachets. The wet mass is passed through a 16-mesh (1.0 mm) screen before drying; post-drying, the granulate is milled through a 30-mesh (600 μm) screen and the fines below 60-mesh (250 μm) are limited to not more than 15% w/w to prevent flow problems during downstream sachet filling or tableting. Residual moisture at drying endpoint is specified at 2–4% as determined by loss on drying at 105°C for 15 minutes using a Halogen moisture analyzer calibrated against USP <731> reference method. Product bed temperatures exceeding 45°C during the constant-rate drying phase initiate measurable ester cleavage, and drying curves should be validated to confirm that the falling-rate phase does not exceed 40°C at the product surface, where localized hot spots in the fluidized bed caused by defluidization zones can produce an assay loss of 1–3% relative to label claim. The final granules are filled into unit-dose sachets at volumes of 1–5 g using a vertical form-fill-seal machine with moisture barrier film; sachet seal integrity is verified by vacuum leak testing per USP <1207> or equivalent, and the finished granulate is tested for bulk density (0.4–0.6 g/cm³), tapped density (0.55–0.75 g/cm³), and Carr's compressibility index (15–20%) to ensure reproducible sachet filling on automatic dispensing lines. Granules for oral administration in equine practice are often mixed into feed; palatability screening using a two-pan preference test in a small number of horses may be conducted by the formulator, but published systematic palatability data for NPP granules in equine species is limited, and the practical specification is visual acceptance by the animal within 30 minutes of feed presentation.

Granule formulations also serve as an intermediate for subsequent compression into tablets or for preparation of extemporaneous oral suspensions in compounding pharmacies. The granular product specification must therefore include particle size distribution by sieve analysis per USP <786>, with the mass fraction retained on the 20-mesh (850 μm) sieve not exceeding 10% and the fraction passing the 80-mesh (180 μm) sieve not exceeding 20%. Bulk powder testing for microbial limits per USP <61> and USP <62> applies to nonsterile oral dosage forms, with total aerobic microbial count ≤ 10³ CFU/g and total combined yeast and mold count ≤ 10² CFU/g, and the absence of Escherichia coli, Salmonella species, and Staphylococcus aureus. Water activity of the dried granules should be maintained below 0.60 to limit microbial proliferation and ester hydrolysis during storage; the use of desiccant canisters in the primary packaging closure is recommended where distribution to tropical climates is anticipated. Stability testing of granulate formulations follows ICH Q1A(R2) bracketing and matrixing where strengths are proportionally similar; a reduced design with testing at 0, 3, 6, 9, 12, 18, 24, and 36 months under long-term conditions (25°C/60% RH) and at 0, 3, and 6 months under accelerated conditions (40°C/75% RH) is generally acceptable when bracketing covers the lowest and highest granule strengths. The free nandrolone degradant specification for granules should be tightened compared with injectable products because oral administration exposes the drug substance to gastric acid, where partial acid-catalyzed ester hydrolysis can occur in vivo; however, the pre-administration granulate should still meet the API release specification for related substances, and the certificate of analysis should report both free nandrolone and total related substances as separate identified peaks. Batch-to-batch granule friability, measured as the percentage of granulate passing a 60-mesh sieve after 20 minutes of vibration in a sieve shaker, should not exceed 5% to limit dusting during downstream processing and to protect operator exposure under occupational health limits; the API is a potent steroid, and engineering controls including local exhaust ventilation and personal protective equipment are required during weighing, blending, and milling operations.

Sub-10 μm Particle Engineering and Terminal Sterilization Conflicts in Aqueous NPP Suspension Injections

Aqueous suspension injectables containing nandrolone phenylpropionate for veterinary use address the need for rapid administration without the oily vehicle associated with delayed depot release and injection-site discomfort. The critical quality attribute that defines this presentation is the particle size distribution of the micronized API, because intramuscular and subcutaneous administration of aqueous suspensions requires particles to pass through a 21G or 23G needle smoothly without clogging while retaining sufficient particle size to provide sustained dissolution from the injection site. Micronization of NPP is performed using a jet mill with compressed air at 6–8 bar and feed rate adjusted to produce a D₉₀ below 10 μm and D₅₀ between 2–5 μm as measured by laser diffraction per USP <429> using a wet dispersion method with 0.1% w/v polysorbate 80 in purified water as dispersant. The micronized powder is then formulated into an aqueous vehicle containing polysorbate 80 at 0.1–0.5% w/v as wetting agent, sodium carboxymethylcellulose (medium viscosity grade, 200–400 mPa·s for 2% w/v solution at 25°C) at 0.5–1.5% w/v as suspending agent, sodium chloride or dextrose as isotonicity adjuster (target osmolality 270–330 mOsm/kg per USP <785>), and benzyl alcohol at 0.9% w/v as preservative for multi-dose vial presentations. The suspension is prepared by high-shear dispersion of the micronized API into a pre-hydrated CMC gel phase using a rotor-stator homogenizer at 10,000–15,000 rpm for 10–20 minutes; air entrainment is subsequently removed by vacuum deaeration at −0.7 to −0.9 bar for 30 minutes with slow anchor stirring. Sterilization of aqueous NPP suspensions presents a fundamental process conflict: terminal steam sterilization at 121°C causes particle growth through Ostwald ripening and partial dissolution-reprecipitation, shifting the D₉₀ from below 10 μm to above 25 μm in some batches, while also producing measurable ester hydrolysis in the aqueous environment. Consequently, aseptic processing is mandatory: the API is sterilized by gamma irradiation at 25–40 kGy per ISO 11137-1 before micronization, the vehicle components are sterilized by steam autoclaving at 121°C for 20 minutes or by 0.22 μm filtration, and the final suspension is compounded and filled within a Grade A environment conforming to EU GMP Annex 1.

The aseptic processing workflow introduces validated process parameters that are not documented in compendial monographs for this specific dosage form, so the manufacturer must generate process validation data. Environmental monitoring during compounding and filling must demonstrate continuous compliance with Grade A viable counts ≤ 1 CFU/m³ and nonviable particle counts ≥ 0.5 μm at ≤ 3,520/m³ in operation, with settle plate and active air sampling results trending within alert levels. Media fill trials using tryptic soy broth performed every 6 months with a minimum of 3,000 filled units must demonstrate zero contaminated units to meet the USP <1116> acceptance criterion. The final suspension specification includes sedimentation volume (sediment height expressed as a fraction of total suspension height after standing) not less than 0.8 at 24 hours, redispersibility demonstrated by not more than 10 manual inversions to produce a uniform suspension, and syringeability through a 21G needle with an extrusion force not exceeding 20 N at 25°C and a withdrawal volume of 2 mL from a 10 mL multi-dose vial. Particle size distribution of the finished suspension should remain stable over the shelf life; accelerated stability at 40°C/75% RH for 6 months should not show D₉₀ growth exceeding 20% of the initial value, and long-term storage at 25°C/60% RH for 24 months should maintain D₉₀ below 15 μm. The viscosity of the final suspension is typically between 20–80 mPa·s at 25°C using a rotational viscometer with spindle 2 at 60 rpm; lower viscosities reduce suspending capacity, while higher viscosities impede syringe withdrawal and injection through narrow-gauge needles. Multi-dose vials require preservative efficacy testing per USP <51> against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and Aspergillus brasiliensis; the preservative system containing benzyl alcohol at 0.9% w/v must achieve not less than 1.0 log₁₀ reduction for bacteria at 7 days and not less than 1.0 log₁₀ reduction for fungi at 14 days with no increase at 28 days.

A documented failure mode in aqueous NPP suspension manufacturing is the formation of API agglomerates during the transition from micronized powder to wetted suspension. The micronized powder has a high surface free energy and electrostatic charge after jet milling, causing it to form loose agglomerates that resist wetting by the aqueous vehicle. The corrective process sequence involves pre-wetting the API with a small volume of polysorbate 80 solution at 0.5% w/v using a mortar and pestle or low-shear planetary mixer before introduction into the bulk vehicle; skipping this step results in flocculates that do not redisperse and may block 21G needles during administration. Charge stabilisation is not the primary mechanism in this formulation; steric stabilisation provided by adsorbed polysorbate 80 and CMC-derived rheological structuring jointly reduce particle-particle contact. Zeta potential measurements on the suspension are typically between −20 mV and −35 mV due to the anionic CMC coating, but published zeta potential data for NPP sterile suspensions specifically is limited. The specification for injectable suspension pH should fall within 5.0–7.5, because acidic conditions accelerate ester hydrolysis while alkaline conditions increase the rate of oxidative degradation at the phenylpropionate aromatic ring. Oxygen scavenging through nitrogen overlay during compounding and headspace nitrogen purging of filled vials limits oxidative degradation; residual oxygen in the headspace should be maintained below 3% v/v as measured by non-destructive laser headspace analysis. Terminal products for aqueous suspension injection must be labeled with “shake well before use” and stored upright in secondary packaging to prevent caking at the vial bottom; validated shipping studies per ISTA 3A or equivalent should confirm that the suspension redisperses fully after 72 hours of continuous vibration simulating road transport.

Compounding pharmacies preparing extemporaneous NPP oral suspensions from the granular or powder form represent a further downstream application where analytical control is frequently absent. The pharmacist compounds a suspension using a vehicle selected from published compounding references, typically consisting of Ora-Plus oral suspending vehicle, Ora-Sweet syrup vehicle, or a simple syrup and CMC combination, at strengths of 2.5–10 mg/mL. Stability of NPP in these compounded suspensions is pH-dependent and vehicle-dependent, with published stability data for related nandrolone esters in oral suspension vehicles suggesting a beyond-use date of 14–30 days under refrigeration (2–8°C) is justifiable, while ambient storage beyond 7 days risks ester hydrolysis and microbiological proliferation in preserved syrups. Sterile compounding of NPP injectable products for individual animals under AMDUCA follows USP <797> standards including compounder hand hygiene, gloved fingertip testing, and surface sampling; beyond-use dates for nonsterile-to-sterile compounding of injectable products using a validated sterilizing filtration process must not exceed 45 days under refrigeration or 24 hours at controlled room temperature per USP <797> risk levels. Extemporaneous capsule preparation from bulk NPP powder requires the compounding pharmacist to establish content uniformity through geometric dilution and to maintain a master formulation record with assigned beyond-use date not exceeding 6 months for non-aqueous solid dosage forms under USP <795>. These compounding parameters are listed because the API supplier's documentation—including certificate of analysis, sterility claim (if applicable), and particle size distribution—must align with the compounding pharmacist's risk assessment under USP <800> for hazardous drug handling where the steroid is classified as a hazardous drug under NIOSH criteria due to potential endocrine disruption in occupational exposure scenarios.